ALN KHK
Alternative Names: ALN-KHKLatest Information Update: 15 Dec 2023
At a glance
- Originator Alnylam Pharmaceuticals
- Class Antihyperglycaemics; Small interfering RNA
- Mechanism of Action Fructokinases expression modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Type 2 diabetes mellitus
Most Recent Events
- 13 Dec 2023 Safety, pharmacokinetics and pharmacodynamics data from a phase I/II trial in Type 2 diabetes mellitus released by Alnylam Pharmaceuticals
- 10 Mar 2023 Phase-I/II clinical trials in Type 2 diabetes mellitus in Canada (SC, Injection) (NCT05761301)
- 22 Dec 2022 Alnylam Pharmaceuticals submits a clinical trial authorization application with the Health Canada in Canada for Type 2 diabetes mellitus